{"a":[{"_":"FDA greenlights Revolution Medicines' pancreatic cancer gamechanger","$":{"href":"/pharma/fda-greenlights-revolution-medicines-pancreatic-cancer-gamechanger","hreflang":"en"}}]}
RegulatoryapproveddaraxonrasibPositive
AI Analysis
Summary
Revolution Medicines' Ras inhibitor daraxonrasib has received FDA approval for treating metastatic pancreatic cancer, following positive clinical data presented at ASCO in May.
Outcome Details
FDA approval for metastatic pancreatic cancer
Importance:9/10
Sentiment:
0.95
FDA approvaloncologypancreatic cancerRas inhibitorASCO
Related Companies
Read the original article
Published by FiercePharma on August 26, 2026 11:31 AM